1-11 of 11
Bradley J. Monk
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract A016: NXP800, a novel, small molecule GCN2 kinase activator, demonstrates potent single-agent activity in ARID1A and ARID1B-deficient endometrial cancer xenograft models

Ramez N. Eskander, Bradley J. Monk, Brian M. Slomovitz, Enrique Poradosu, Allison Woods, Shay Shemesh, Paul Clarke, Robert Te Poele, Marissa Powers, Paul Workman, Shannon N. Westin
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (5_Supplement): A016.
https://doi.org/10.1158/1557-3265.ENDO24-A016
Published: 01 March 2024
View article titled, Abstract A016: NXP800, a novel, small molecule GCN2 kinase activator, demonstrates potent single-agent activity in ARID1A and ARID1B-deficient endometrial cancer xenograft models
Journal Articles

Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer

Rachel N. Grisham, Ignace Vergote, Susana Banerjee, Esther Drill, Elsa Kalbacher, Mansoor Raza Mirza, Ignacio Romero, Peter Vuylsteke, Robert L. Coleman, Felix Hilpert, Amit M. Oza, Anneke Westermann, Martin K. Oehler, Sandro Pignata, Carol Aghajanian, Nicoletta Colombo, David Cibula, Kathleen N. Moore, Josep M. del Campo, Regina Berger, Christian Marth, Jalid Sehouli, David M. O'Malley, Cristina Churruca, Gunnar Kristensen, Andrew Clamp, John Farley, Gopa Iyer, Isabelle Ray-Coquard, Bradley J. Monk
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (20): 4068–4075.
https://doi.org/10.1158/1078-0432.CCR-23-0621
Published: 13 October 2023
View article titled, Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer
Open the PDF for Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract NT-101: QUADRA: A PHASE 2, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE SINGLE-AGENT NIRAPARIB TREATMENT IN PATIENTS WITH RELAPSED OVARIAN CANCER (ROC) WHO HAVE RECEIVED ≥3 PRIOR CHEMOTHERAPY REGIMENS

Kathleen Moore, Angeles Secord, Melissa Geller, David Miller, Noelle Cloven, Gini Fleming, Andrea E. Wahner Hendrickson, Masoud Azodi, Paul Disilvestro, Amit Oza, Mihaela Cristea, Jonathan S. Berek, John Chan, Yong Li, Kaiming Sun, Katarina Luptakova, Ursula A. Matulonis, Bradley J. Monk
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (22_Supplement): NT-101.
https://doi.org/10.1158/1557-3265.OVCASYMP18-NT-101
Published: 15 November 2019
View article titled, Abstract NT-101: QUADRA: A PHASE 2, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE SINGLE-AGENT NIRAPARIB TREATMENT IN PATIENTS WITH RELAPSED OVARIAN CANCER (ROC) WHO HAVE RECEIVED ≥3 PRIOR CHEMOTHERAPY REGIMENS
Journal Articles

Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemoimmunotherapy

Bradley J. Monk, Andrea Facciabene, William E. Brady, Carol A. Aghajanian, Paula M. Fracasso, Joan L. Walker, Heather A. Lankes, Kristi L. Manjarrez, Gwenn-äel H. Danet-Desnoyers, Katherine M. Bell-McGuinn, Carolyn K. McCourt, Alexander Malykhin, Robert M. Hershberg, George Coukos
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (8): 1955–1966.
https://doi.org/10.1158/1078-0432.CCR-16-1453
Published: 13 April 2017
View article titled, Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemoimmunotherapy
Open the PDF for Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemoimmunotherapy in another window
Includes: Supplementary data
Journal Articles

Abstract B71: Old age and chemotherapy contribute to the selection of PPM1D somatic mosaic mutations in ovarian cancer.

Maria I. Harrell, Barbara M. Norquist, Tom Walsh, Mark F. Brady, Ming K. Lee, Robert Hershberg, Kimberly R. Kalli, Heather Lankes, Eric Q. Konnick, Colin C. Pritchard, Bradley J. Monk, John K. Chan, Robert Burger, Scott H. Kaufmann, Michael J. Birrer, Elizabeth M. Swisher
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (2_Supplement): B71.
https://doi.org/10.1158/1557-3265.OVCA15-B71
Published: 15 January 2016
View article titled, Abstract B71: Old age and chemotherapy contribute to the selection of PPM1D somatic mosaic mutations in ovarian cancer.
Journal Articles

Prospective Validation of Pooled Prognostic Factors in Women with Advanced Cervical Cancer Treated with Chemotherapy with/without Bevacizumab: NRG Oncology/GOG Study

Krishnansu S. Tewari, Michael W. Sill, Bradley J. Monk, Richard T. Penson, Harry J. Long, III, Andrés Poveda, Lisa M. Landrum, Mario M. Leitao, Jubilee Brown, Thomas J.A. Reid, Helen E. Michael, David H. Moore
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (24): 5480–5487.
https://doi.org/10.1158/1078-0432.CCR-15-1346
Published: 14 December 2015
View article titled, Prospective Validation of Pooled Prognostic Factors in Women with Advanced Cervical Cancer Treated with Chemotherapy with/without Bevacizumab: NRG Oncology/GOG Study
Open the PDF for Prospective Validation of Pooled Prognostic Factors in Women with Advanced Cervical Cancer Treated with Chemotherapy with/without Bevacizumab: NRG Oncology/GOG Study in another window
Includes: Supplementary data
Journal Articles

Development of Olaparib for BRCA-Deficient Recurrent Epithelial Ovarian Cancer

Krishnansu S. Tewari, Ramez N. Eskander, Bradley J. Monk
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (17): 3829–3835.
https://doi.org/10.1158/1078-0432.CCR-15-0088
Published: 31 August 2015
View article titled, Development of Olaparib for BRCA-Deficient Recurrent Epithelial Ovarian Cancer
Open the PDF for Development of Olaparib for BRCA-Deficient Recurrent Epithelial Ovarian Cancer in another window
Journal Articles

Abstract AS27: VTX-2337, a TLR8 agonist, plus chemotherapy in recurrent ovarian cancer: preclinical and phase 1 data by the gynecologic oncology group

Bradley J. Monk, William E. Brady, Heather A. Lankes, Andrea Facciabene, Kristi L. Manjarrez, Robert M. Hershberg, Paula M. Fracasso, Katherine M. Bell-McGuinn, Joan L. Walker, Carolyn K. McCourt, Carol Aghajanian, George Coukos
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (16_Supplement): AS27.
https://doi.org/10.1158/1557-3265.OVCASYMP14-AS27
Published: 15 August 2015
View article titled, Abstract AS27: VTX-2337, a TLR8 agonist, plus chemotherapy in recurrent ovarian cancer: preclinical and phase 1 data by the gynecologic oncology group
Journal Articles

New Strategies in Advanced Cervical Cancer: From Angiogenesis Blockade to Immunotherapy

Krishnansu S. Tewari, Bradley J. Monk
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (21): 5349–5358.
https://doi.org/10.1158/1078-0432.CCR-14-1099
Published: 30 October 2014
View article titled, New Strategies in Advanced Cervical Cancer: From Angiogenesis Blockade to Immunotherapy
Open the PDF for New Strategies in Advanced Cervical Cancer: From Angiogenesis Blockade to Immunotherapy in another window
Journal Articles

Stress, Immunity, and Cervical Cancer: Biobehavioral Outcomes of a Randomized Clinical Trail

Edward L. Nelson, Lari B. Wenzel, Kathryn Osann, Aysun Dogan-Ates, Nissa Chantana, Astrid Reina-Patton, Amanda K. Laust, Kevin P. Nishimoto, Alexandra Chicz-DeMet, Nefertiti du Pont, Bradley J. Monk
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (7): 2111–2118.
https://doi.org/10.1158/1078-0432.CCR-07-1632
Published: 01 April 2008
View article titled, Stress, Immunity, and Cervical Cancer: Biobehavioral Outcomes of a Randomized Clinical Trail
Open the PDF for Stress, Immunity, and Cervical Cancer: Biobehavioral Outcomes of a Randomized Clinical Trail in another window
Includes: Supplementary data
Journal Articles

Early Stage Cervical Cancers Containing Human Papillomavirus Type 18 DNA Have More Nodal Metastasis and Deeper Stromal Invasion

Samuel S. Im, Sharon P. Wilczynski, Robert A. Burger, Bradley J. Monk
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (11): 4145–4150.
Published: 30 September 2003
View article titled, Early Stage Cervical Cancers Containing Human Papillomavirus Type 18 DNA Have More Nodal Metastasis and Deeper Stromal Invasion
Open the PDF for Early Stage Cervical Cancers Containing Human Papillomavirus Type 18 DNA Have More Nodal Metastasis and Deeper Stromal Invasion in another window